We recently published our article 10 Stocks Under $10 Analysts Believe Could Soar 200%. In this article, we discuss Larimar Therapeutics Inc. (NASDAQ:LRMR) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.

Stocks trading below $10 have always attracted investors looking for outsized returns. The appeal is easy to understand: a stock rising from $5 to $15 delivers a 200% gain, meaning the investment triples in value. However, a low share price does not automatically mean a company is cheap.

One useful piece of market trivia is that share price and company size are not the same thing. A stock trading at $6 can still represent a multibillion-dollar business if the company has hundreds of millions of shares outstanding. That is why investors searching for the best stocks under $10 should also examine market capitalization, revenue growth, profitability, debt, cash flow, and long-term business prospects.

The companies featured in this article are not small penny stocks. Each has a market capitalization of more than $2 billion and carries a consensus analyst price target suggesting at least 200% upside.

Small-Cap Stocks Are Gaining Momentum

The search for 10 stocks under $10 that could soar 200% comes as smaller companies begin outperforming the broader U.S. stock market.

On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, said small-cap stocks could continue delivering above-market returns because their valuations remain attractive compared with large-cap shares.

During 2026, the Morningstar U.S. Small Cap Market Index gained 14%, outperforming the 10.7% increase recorded by the broader Morningstar U.S. Market.

This performance is notable because U.S. small-cap stocks have generally lagged their mid-cap and large-cap peers over the past 15 years. That prolonged underperformance has left many smaller companies trading at discounted valuations, creating potential opportunities for investors looking for undervalued stocks under $10.

The small-cap rally has continued despite a volatile year shaped by geopolitical tensions, including the Iran-U.S. conflict. Latin American stocks have also performed well since the beginning of the war, supported partly by the region’s exposure to oil and other commodities.

Small Caps May Offer Better Diversification

Pappalardo also pointed to diversification as another reason investors may consider small-cap stocks.

Although the S&P 500 includes around 500 companies, approximately 40% of the index is concentrated in its 10 largest holdings. This means a relatively small group of mega-cap companies can have an enormous influence on the performance of the broader market.

Small-cap indexes are generally less concentrated. Their performance is spread across a wider range of industries, including healthcare, financial services, industrials, energy, consumer products, and technology.

This broader exposure could appeal to investors who believe the market has become too dependent on a handful of large technology companies. It may also create opportunities to find high-upside stocks under $10 that are overlooked by investors focused primarily on the biggest names on Wall Street.

Why Stocks Under $10 Can Produce Large Returns

Low-priced stocks can generate dramatic percentage gains because even a relatively small dollar increase can translate into a large return.

For example, a stock rising from $3 to $6 doubles in value. If it reaches $9, it produces a 200% gain. However, the same mathematics also works in reverse. A decline from $6 to $3 results in a 50% loss.

That is why stocks with triple-digit upside potential usually come with considerable risk. A depressed stock price may reflect temporary market pessimism, but it can also signal weak earnings, high debt, slowing demand, regulatory problems, or uncertainty surrounding the company’s business model.

Analyst price targets should therefore be treated as research tools rather than guarantees. A consensus estimate showing 200% upside means analysts see significant recovery potential, but the company may still need to meet ambitious revenue, earnings, or operational expectations.

Small-Cap Valuations Remain Appealing

Morningstar Wealth believes small-cap stocks are more undervalued than they have been in years, while large-cap stocks currently appear expensive.

That valuation gap could support further gains if investors begin shifting money away from highly valued mega-cap stocks and toward smaller companies with stronger recovery potential.

Still, not every inexpensive stock will become a winner. The strongest opportunities may be found in companies with improving fundamentals, manageable debt, competitive advantages, and identifiable growth catalysts.

With that background, let’s examine the 10 stocks under $10 that could soar 200%.

CHECK THIS OUT: Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years andTop 10 Cheap Stocks Under $10 To Buy Now.

Our Methodology

In order to come up with our list of the 10 stocks under $10 that could soar 200%, we screened U.S.-listed stocks trading below $10 with market capitalizations above $2 billion, shortlisted those with at least 200% consensus upside as of the July 10 close, and ranked the 10 qualifying companies in ascending order based on their projected upside.

10 Stocks Under $10 Analysts Believe Could Soar 200%

8. Larimar Therapeutics Inc. (NASDAQ:LRMR)

Larimar Therapeutics Inc. (NASDAQ: LRMR) occupies the eighth position among the best stocks under $10 that could triple, with shares recently trading at approximately $3.69 after gaining 0.54%. The clinical-stage biotechnology company is developing treatments for rare diseases and is currently centered on Nomlabofusp, its experimental therapy for Friedreich’s ataxia.

On June 29, Larimar Therapeutics Inc. (NASDAQ: LRMR) announced that it had submitted the first module of its Biologics License Application to the U.S. Food and Drug Administration. The company is seeking accelerated approval for Nomlabofusp and plans to submit the remaining portions of the application during the second half of 2026.

The beginning of a rolling BLA submission represents a major regulatory milestone for a biotechnology company. Rather than waiting until every section of the application is complete, a rolling submission can allow the FDA to begin reviewing certain modules while the company prepares the rest. This can make the regulatory process more efficient, although it does not guarantee approval.

Larimar Therapeutics Inc. (NASDAQ: LRMR) is pursuing accelerated approval, a regulatory pathway intended for treatments that address serious conditions and may provide meaningful advantages over available therapies. Under this approach, the FDA can consider approving a treatment based on a surrogate endpoint that is reasonably likely to predict clinical benefit.

In the case of Nomlabofusp, the company is relying on skin frataxin as a new surrogate endpoint. Frataxin is a protein that is deficient in people with Friedreich’s ataxia. The disease is a rare inherited disorder that progressively damages the nervous system and can lead to problems with movement, balance, speech, heart function, and other essential activities.

Larimar Therapeutics Inc. (NASDAQ: LRMR) also reported positive findings from an open-label study involving adult patients who received daily injections of Nomlabofusp. The treatment is designed to deliver frataxin into the mitochondria of patients’ cells, addressing the underlying protein deficiency associated with Friedreich’s ataxia.

President and Chief Executive Officer Carole Ben-Maimon described the data as an important advancement in the development of the therapy. According to the company, the FDA confirmed that the existing data package could support an accelerated approval application using skin frataxin as the surrogate endpoint.

This regulatory alignment is a significant part of the bullish case for Larimar Therapeutics Inc. (NASDAQ: LRMR). Smaller biotechnology companies can lose substantial time and capital when regulators require additional studies or disagree with a proposed approval pathway. Clearer communication from the FDA can reduce some uncertainty and help management focus its resources on completing the application.

Still, accelerated approval is not a shortcut around the need to prove that a therapy works. Companies that receive accelerated approval are generally required to complete confirmatory studies to verify the expected clinical benefit. If those trials fail, are delayed, or do not confirm the treatment’s effectiveness, regulators can take steps to restrict or withdraw the product.

On June 30, Baird analyst Christopher Chen reduced his price target for Larimar Therapeutics Inc. (NASDAQ: LRMR) from $7 to $5. Despite the downward revision, the $5 target still represented potential upside of more than 53% from the prevailing share price. Chen also reiterated an Outperform rating on the stock.

The analyst revised the firm’s financial and valuation model following the company’s update on Nomlabofusp. The new information appeared to support potential clinical benefits but also raised safety considerations that investors will need to watch carefully.

Safety is especially important for a therapy intended for chronic or repeated administration. Even when a drug shows biological activity, regulators and physicians must determine whether its benefits outweigh its risks. Any serious adverse events, dosing limitations, immune reactions, or treatment-related complications could affect Nomlabofusp’s approval prospects and commercial adoption.

Larimar Therapeutics Inc. (NASDAQ: LRMR) describes itself as a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using a cell-penetrating peptide technology platform. Its lead program, also known as CTI-1601 or Nomlabofusp, is being evaluated through ongoing clinical development, including a Phase 2 open-label extension program.

The company’s technology is designed to transport functional proteins into cells and direct them toward specific cellular compartments. In theory, such an approach could eventually have applications beyond Friedreich’s ataxia, although the immediate investment thesis remains tied overwhelmingly to Nomlabofusp.

That concentration creates both opportunity and risk. If Nomlabofusp receives approval and demonstrates meaningful benefits for patients, Larimar Therapeutics Inc. (NASDAQ: LRMR) could gain access to a rare-disease market with significant unmet need and limited treatment options. Rare-disease therapies can command premium pricing because they address small patient populations and often require specialized development programs.

On the other hand, a regulatory setback or major safety concern involving Nomlabofusp could have an outsized effect on the company’s valuation. Investors considering Larimar Therapeutics Inc. (NASDAQ: LRMR) should therefore follow the completion of the BLA submission, FDA feedback, safety data, confirmatory trial requirements, manufacturing readiness, and the company’s cash position.

For investors looking for rare-disease stocks, biotechnology stocks under $5, or clinical-stage stocks with regulatory catalysts, Larimar Therapeutics Inc. (NASDAQ: LRMR) deserves attention. However, it remains a speculative investment whose performance will likely be determined by regulatory execution and the clinical profile of one primary treatment candidate.

YOU MUST READ THIS: 10 Robotics Stocks to Buy Now as Amazon (AMZN) Hits 1M Robots

Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.